BTK Inhibitors Development Services

Alfa Cytology has developed a comprehensive service focused on the development of inhibitors targeting Brenton tyrosine kinase (BTK). We provide tailored solutions for the discovery and development of BTK inhibitors that can help make informed decisions and improve chances of success. By leveraging our expertise and resources, we aim to enhance your chances of success in developing effective BTK inhibitors.

Introduction to BTK

BTK is an enzyme that plays a crucial role in B-cell development and function. BTK is involved in multiple signaling pathways that regulate B-cell receptor (BCR) signaling, cytokine receptor signaling, and cellular adhesion. Given its critical role in B-cell signaling, BTK has emerged as an important therapeutic target, particularly in B-cell malignancies such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).

Fig. 1. Role of BTK in signaling pathways. (Alu, A. et al., 2022)

Discovery of BTK Inhibitors

• We employ a specialized approach that involves designing covalent irreversible inhibitors that specifically target Cys481 within the ATP binding pocket. This strategy aims to enhance the efficacy and expand the target spectrum of BTK inhibitors.
• By utilizing our expertise in drug design and molecular engineering, we optimize the chemical structure of the inhibitors to ensure potent and selective binding to the BTK enzyme. The covalent nature of these inhibitors provides a durable interaction with the target, leading to improved efficacy and prolonged inhibition of BTK activity.

BTK Inhibitors Resistance Solution

• We offer comprehensive services to address drug resistance caused by the Cys481 mutation in BTK. Our approach focuses on designing and developing BTK inhibitors tailored to target the H3 selective pocket in BTK's inactive conformation.
• We provide molecular design improvement and optimization services for existing BTK inhibitors. Through the addition and replacement of key functional groups, we modify the molecular conformation of these inhibitors, enhancing their ability to specifically target BTK and improving their safety and effectiveness.
• In addition, our services encompass the utilization of phenotypic screening to identify potential candidates for BTK inhibitors from drugs originally developed to treat other diseases. This approach enables us to explore new avenues for BTK inhibition and broaden the range of available therapeutic options.
• We specialize in providing BTK development services to address acquired drug resistance associated with C481S BTK mutants. Leveraging our advanced technologies, we induce the ubiquitin degradation of the mutant BTK protein, effectively bypassing drug resistance mechanisms. This approach allows for the development of novel strategies to overcome resistance and enhance the efficacy of BTK-targeted therapies.

Advantages of Our Services

• Development of novel BTK inhibitors.
• Perfect drug optimization and improved services.
• Years of experience in developing BTK inhibitors.
• Advanced technology and experimental platform.

Alfa Cytology has a perfect set of BTK Inhibitors discovery and solutions. By choosing our comprehensive service for BTK inhibitor development, you gain access to our specialized expertise, state-of-the-art facilities, and collaborative approach, positioning you for success in advancing potential therapies targeting Brenton's tyrosine kinase. Contact us to discuss your specific needs and how our services can support your drug development.